DMD was first described by French neurologist Guillaume Benjamin Amand Duchenne in the 1860s. However, until the 1980s, ...

DMD treatment KER-065 showed a good safety profile in a Phase 1 clinical trial with no serious side effects seen in healthy ...

And it's first such treatment in his class," said ... Karachunski said there are many more muscular dystrophy treatments that are currently in clinical trials that he believes could help Colton ...

A new paper published in Gene Therapy raises serious concerns about the effectiveness of gene therapy for Duchenne muscular dystrophy (DMD), after the treatment failed to show significant benefit ...

None of the eteplirsen-treated patients reached a left ventricular ejection fraction below 50% compared with 22.1% of ...

Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.

Kye Pharmaceuticals, Inc. ("Kye") announced today it has submitted a New Drug Submission (NDS) to Health Canada for the ...

This cardiomyopathy eventually leads to heart failure, which is currently the leading cause of death among those with DMD. Treatment options are limited and there is no cure. Statements in this ...

DMD is a devastating genetic disorder that leads to progressive muscle weakness and eventually death, typically due to cardiomyopathy. There are currently limited treatment options available.

DMD is a severe genetic disorder leading to ... Current treatments are limited, and there is no cure. This news is based on a press release statement from Capricor Therapeutics.

Unmet need for DMD patients remains high as there are no approved therapies with ... the dystrophin protein by excising exons 45-55 as a treatment; the suitability of PBGENE-DMD for the treatment ...

there are treatment options including occupational and physical therapy, foot and ankle braces, and wheelchairs. Children with Becker muscular dystrophy may start walking at a later age than usual.